NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD
Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 562 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes NBIX very considerable for growth and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 9.18% | ||
ROE | 13.18% | ||
ROIC | 13.2% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 24.75% | ||
PM (TTM) | 14.49% | ||
GM | 98.56% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 7.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.4 | ||
Quick Ratio | 3.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 39.62 | ||
Fwd PE | 18.11 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 20.75 | ||
EV/EBITDA | 14.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
116.87
-3.56 (-2.96%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 39.62 | ||
Fwd PE | 18.11 | ||
P/S | 4.91 | ||
P/FCF | 20.75 | ||
P/OCF | 19.42 | ||
P/B | 4.47 | ||
P/tB | 4.53 | ||
EV/EBITDA | 14.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 9.18% | ||
ROE | 13.18% | ||
ROCE | 18.16% | ||
ROIC | 13.2% | ||
ROICexc | 32.81% | ||
ROICexgc | 33.77% | ||
OM | 24.75% | ||
PM (TTM) | 14.49% | ||
GM | 98.56% | ||
FCFM | 23.66% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 140.96% | ||
Cap/Sales | 1.62% | ||
Interest Coverage | 364.38 | ||
Cash Conversion | 97.59% | ||
Profit Quality | 163.26% | ||
Current Ratio | 3.4 | ||
Quick Ratio | 3.28 | ||
Altman-Z | 7.7 |